Financial Summary (All financials)
| In millions, except per share items | Sep-30-22 | Sep-30-21 | Sep-30-20 | Sep-30-19 | Sep-30-18 | Sep-30-17 | Sep-30-16 | Sep-30-15 |
| Revenues | 8,275.3 | 8,425.5 | 5,566.5 | 5,669.4 | 6,319.1 | 6,392.2 | 6,618.0 | 7,948.7 |
| Revenue growth | -1.8% | 51.4% | -1.8% | -10.3% | -1.1% | -3.4% | -16.7% | -6.4% |
| Cost of goods sold | 3,308.7 | 3,189.4 | 2,021.8 | 1,718.3 | 128.6 | 121.3 | 134.1 | 132.7 |
| Gross profit | 4,966.6 | 5,236.1 | 3,544.7 | 3,951.1 | 6,190.5 | 6,270.9 | 6,483.9 | 7,816.0 |
| Gross margin | 60.0% | 62.1% | 63.7% | 69.7% | 98.0% | 98.1% | 98.0% | 98.3% |
| Sales and marketing | 1,845.6 | 2,105.8 | 1,703.1 | 1,819.6 | 2,039.7 | 2,130.9 | 2,209.9 | 2,762.3 |
| Research and development | 500.2 | 486.1 | 288.4 | 258.5 | 243.9 | 219.8 | 207.3 | 224.3 |
| General and administrative | 564.9 | 537.2 | 450.3 | 391.4 | 1,788.3 | 1,655.9 | 1,701.0 | 348.5 |
| EBITA | 2,055.9 | 2,107.0 | 1,102.9 | 1,481.6 | 2,120.4 | 2,268.2 | 2,376.1 | 3,047.7 |
| EBITA margin | 24.8% | 25.0% | 19.8% | 26.1% | 33.6% | 35.5% | 35.9% | 38.3% |
| Amortization of intangibles | 282.0 | 232.0 | 54.0 | 14.7 | 1.8 | 3.9 | 10.4 | 20.1 |
| EBIT | 1,773.9 | 1,875.0 | 1,048.9 | 1,466.9 | 2,118.6 | 2,264.3 | 2,365.7 | 3,027.6 |
| EBIT margin | 21.4% | 22.3% | 18.8% | 25.9% | 33.5% | 35.4% | 35.7% | 38.1% |
| Pre-tax income | 1,729.4 | 2,444.2 | 1,017.9 | 1,647.8 | 2,215.2 | 2,549.1 | 2,499.8 | 3,028.4 |
| Income taxes | 396.2 | 349.6 | 230.8 | 442.3 | 1,472.5 | 759.4 | 742.1 | 923.7 |
| Tax rate | 22.9% | 14.3% | 22.7% | 26.8% | 66.5% | 29.8% | 29.7% | 30.5% |
| Net income | 1,333.2 | 2,094.6 | 787.1 | 1,205.5 | 742.7 | 1,789.7 | 1,757.7 | 2,104.7 |
| Net margin | 16.1% | 24.9% | 14.1% | 21.3% | 11.8% | 28.0% | 26.6% | 26.5% |
| |
| Diluted EPS | $2.72 | $4.27 | $1.60 | $2.39 | $1.38 | $3.20 | $3.01 | $3.42 |
| Shares outstanding (diluted) | 489.3 | 490.6 | 492.4 | 504.3 | 538.0 | 559.1 | 583.8 | 614.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|